IDXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
IDEXX Laboratories Inc (IDXX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive hedge fund activity, and promising growth in the pet health sector outweigh the mixed analyst sentiment and minor concerns around margins. The technical indicators also support a bullish trend, making this a solid long-term investment opportunity.
The technical indicators for IDXX are bullish. The MACD histogram is positively expanding at 4.447, RSI is neutral at 66.584, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels with resistance at 659.167 and 673.35, indicating potential for further upside.
Hedge funds are significantly increasing their positions in IDXX, with a 764.05% increase in buying activity over the last quarter.
The company has achieved a 20% annual return since 1994 and is expected to see significant revenue growth from its new InVue DX instrument.
Strong financial performance in Q4 2025, with revenue, net income, and EPS showing double-digit YoY growth.
Analysts have recently lowered price targets, citing concerns about muted Q1 growth, softer 2026 gross margin outlook, and slower inVue placements.
The gross margin dropped slightly by -0.10% YoY in Q4 2025, raising minor concerns about profitability.
In Q4 2025, IDEXX Laboratories reported strong financial results with revenue increasing by 14.28% YoY to $1.09 billion, net income up 14.82% YoY to $248.19 million, and EPS rising 17.56% YoY to 3.08. However, gross margin slightly decreased by -0.10% YoY to 59.74.
Analyst sentiment is mixed. While firms like Barclays and BTIG maintain Overweight/Buy ratings with price targets of $800, others like Piper Sandler and UBS have Neutral ratings and lowered price targets, citing concerns about growth and margin sustainability in 2026.
